Australian pharmaceutical company Amplia Therapeutics Limited (ASX: ATX) on Monday announced positive preclinical data demonstrating the efficacy of its FAK inhibitor, AMP945, in combination with FOLFIRINOX treatment for pancreatic cancer.

The data showed improved survival rates in mice compared to those treated with FOLFIRINOX alone. AMP945 was administered prior to FOLFIRINOX treatment, resulting in a statistically significant increase in survival.

Amplia has filed a patent to protect the use of FAK inhibitors, specifically AMP945, in combination with FOLFIRINOX and related treatment regimens.

Data supports future clinical studies investigating the combination of AMP945 with FOLFIRINOX. The ACCENT trial, currently underway, is evaluating AMP945 with gemcitabine and nab-paclitaxel.

FOLFIRINOX is widely used for pancreatic cancer patients in the US, Canada and Europe, demonstrating a median overall survival of 11.1 months.

Amplia Therapeutics Limited focuses on developing FAK inhibitors for cancer and fibrosis, with a specific emphasis on fibrotic cancers like pancreatic cancer.